Consequently, patients with TP53-mutant AML/MDS have extremely poor outcomes, and, thus, represent a major unmet clinical need (Bejar et al, 2011; Daver et al, 2022; Papaemmanuil et al, 2016; Rucker et al, 2012). Here, TP53 is linked to myelodysplastic syndrome.